NAN - Market Leader & ASX200 Leader!, page-12

It's also about establishing brand recognition and respect in a very high tech/high cost medical devices/materials industry.
The competition for probe cleaning comes pretty much from the established chemical treatments, which are limited in their effectiveness.

Drug resistant bacteria is a growing problem world wide, with very few opportunities to delay/stop the progress of resistance.
Traditional antibiotics are losing their effectiveness, or worse, the overuse of antibiotics is actually resulting in the evolution of lethal super-bugs.

The large pharma's are pouring mega bucks into research to find new drug responses - but bacteria have been on earth for 100's of millions of years, and they quickly adapt to their environments, particularly to drugs/chemicals.
Drug and chemical approaches to dealing with these lethal bacteria have not proven to be effective over time, as this approach doesn't kill 100% of the bacteria - witness the bacterias' ability to mutate and progress into super-bugs. Whereas, Trophon is a mechanical device that's shown to be 100% effective at the bacterial level, leaving no survivors to pass on resistant genetic code.

The major issue is controlling the spread/vector. One of the most dangerous places to contract these life threatening bacteria is in hospitals. Entrée Trophon and NAN tech.

The medial device/drug sector is highly regulated with strict standards administered by government authorities - so, as long as you keep your nose clean and stay out of mischief the field is yours. Once you get your foot in the door you can expand your range of products and uses.

I think if NAN tech (Trophon/mechanical devices v's chemical) proves effective in halting the spread of lethal super-bug bacteria on ultrasound probes and its product development stream maintains Trophon's effectiveness over time, then there are a lot more hospital based applications to be addressed - to isolate the super-bugs and make hospitals a lot safer places to visit.

We could be looking at another CSL, Cochlear.
I'm inclined to double up as the company ticks off the milestones and successes - versus doubling down.

(Long term holder - original parcel at $1.14 )